氯膦酸鹽脂質(zhì)體和PLX5622清除腦部三種巨噬細(xì)胞解決方案
腦淀粉樣血管病 (CAA)(Cerebral amyloid angiopathy:CAA) 是老年人認(rèn)知障礙和腦出血 (ICH) 的主要原因。纖維狀淀粉樣蛋白β蛋白(Aβ)在小血管和毛細(xì)血管內(nèi)的沉積,尤其是β淀粉樣蛋白肽1-40(Aβ40)是CAA的特征。巨噬細(xì)胞譜系細(xì)胞的吞噬行為,包括卵黃囊衍生的小膠質(zhì)細(xì)胞(Microglia),腦駐留血管周圍巨噬細(xì)胞(PeriVascular Macrophages:PVM)和循環(huán)單核細(xì)胞(Ly6Chi)衍生的浸潤巨噬細(xì)胞,對(duì)于Aβ清除至關(guān)重要。巨噬細(xì)胞清除活性受損已被證明會(huì)加劇CAA結(jié)果。另一方面,發(fā)現(xiàn)被吞噬貨物淹沒的巨噬細(xì)胞譜系細(xì)胞獲得了組織破壞特性。載有Aβ的巨噬細(xì)胞在CAA中的病理影響有待研究。
為探討三種巨噬細(xì)胞在腦淀粉樣血管病 (CAA)的功能,研究者使用了荷蘭Liposoma的巨噬細(xì)胞清除劑Clodronate liposomes氯膦酸鹽脂質(zhì)體和飲食給藥的PLX5622。外周血循環(huán)單核細(xì)胞以10ul/g劑量通過腹腔注射來清除;小膠質(zhì)細(xì)胞通過長期飲食喂養(yǎng)PLX5622來清除;腦駐留血管周圍巨噬細(xì)胞通過腦立體定位注射10ul荷蘭Liposoma的巨噬細(xì)胞清除劑Clodronate liposomes氯膦酸鹽脂質(zhì)體來清除。三種巨噬細(xì)胞的清除效果通過流式或者免疫熒光來評(píng)價(jià)。
Peripheral blood monocyte depletion was carried out according to published procedure35. Clodronate liposomes (Liposoma, 10?ml/kg, i.p.) was administered to 12-week-old Tg-SwDI/B mice every 3 days to deplete peripheral monocytes/macrophages prior to sacrifice at day 7. Depletion efficacy was confirmed with flow cytometric analysis.
For microglia depletion, PLX5622 was supplied to 12-week-old Tg-SwDI/B mice in the diet at 1200 PPM (1200?mg/kg of chow), starting 7 days prior to sacrifice36. Depletion efficacy of was confirmed with immunostaining.
Perivascular macrophage depletion was carried out according to published procedure9. 12-week-old Tg-SwDI/B mice were anesthetized with isoflurane and stereotaxically injected with 10?μL of clodronate-containing liposomes into the left lateral ventricle (coordinates from Bregma: anteroposterior, 0.2?mm; mediolateral, 1.2?mm; dorsoventral, 2.3?mm). Animals were sacrificed 7 days later and brains were processed for further analysis. Depletion efficacy of was confirmed with immunostaining.
清除效果:
CD206 (green, PVM marker),見圖a
F4/80 (green, infiltrated macrophages marker,見圖b
Clo ICV:intra-cerebral ventricle injected clodronate liposomes (Clo ICV) ,腦室內(nèi)注射clodronate liposomes
CLO IP:intraperitoneally injected clodronate liposomes (CLO IP),腹腔注射clodronate liposomes
見圖C:CD45和F4/80雙標(biāo)的流式圖,外周血循環(huán)單核細(xì)胞以10ul/g劑量通過腹腔注射來清除,相對(duì)于對(duì)照的6.7%,荷蘭Liposoma的巨噬細(xì)胞清除劑Clodronate liposomes氯膦酸鹽脂質(zhì)體可以清除94%以上的外周血單核細(xì)胞巨噬細(xì)胞。見圖d:小膠質(zhì)細(xì)胞通過長期飲食喂養(yǎng)PLX5622來清除;見圖e:腦駐留血管周圍巨噬細(xì)胞通過腦立體定位注射10ul荷蘭Liposoma的巨噬細(xì)胞清除劑Clodronate liposomes氯膦酸鹽脂質(zhì)體來清除。
論文信息:
論文題目:Macrophage lineage cells-derived migrasomes activate complement-dependent blood-brain barrier damage in cerebral amyloid angiopathy mouse model
期刊名稱:Nature Communications
時(shí)間期卷:14, Article number: 3945 (2023)
在線時(shí)間:2023年7月4日
DOI:doi.org/10.1038/s41467-023-39693-x
產(chǎn)品信息:
貨號(hào):CP-005-005
規(guī)格:5ml+5ml
品牌:Liposoma
產(chǎn)地:荷蘭
名稱:Clodronate Liposomes and Control Liposomes
辦事處:Target Technology(靶點(diǎn)科技)
相關(guān)產(chǎn)品
-
免責(zé)聲明
- 凡本網(wǎng)注明“來源:化工儀器網(wǎng)”的所有作品,均為浙江興旺寶明通網(wǎng)絡(luò)有限公司-化工儀器網(wǎng)合法擁有版權(quán)或有權(quán)使用的作品,未經(jīng)本網(wǎng)授權(quán)不得轉(zhuǎn)載、摘編或利用其它方式使用上述作品。已經(jīng)本網(wǎng)授權(quán)使用作品的,應(yīng)在授權(quán)范圍內(nèi)使用,并注明“來源:化工儀器網(wǎng)”。違反上述聲明者,本網(wǎng)將追究其相關(guān)法律責(zé)任。
- 本網(wǎng)轉(zhuǎn)載并注明自其他來源(非化工儀器網(wǎng))的作品,目的在于傳遞更多信息,并不代表本網(wǎng)贊同其觀點(diǎn)和對(duì)其真實(shí)性負(fù)責(zé),不承擔(dān)此類作品侵權(quán)行為的直接責(zé)任及連帶責(zé)任。其他媒體、網(wǎng)站或個(gè)人從本網(wǎng)轉(zhuǎn)載時(shí),必須保留本網(wǎng)注明的作品第一來源,并自負(fù)版權(quán)等法律責(zé)任。
- 如涉及作品內(nèi)容、版權(quán)等問題,請(qǐng)?jiān)谧髌钒l(fā)表之日起一周內(nèi)與本網(wǎng)聯(lián)系,否則視為放棄相關(guān)權(quán)利。